MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41416-023-02162-9

Медицинская библиотека · British journal of cancer · 2023

Children with chronic myeloid leukaemia treated with front-line imatinib have a slower molecular response and comparable survival compared with adults: a multicenter experience in Taiwan.

Liu Hsi-Che, Kuo Ming-Chung, Wu Kang-Hsi, Chen Tsai-Yun, Chen Jiann-Shiuh, Wang Ming-Chung, Lin Tung-Liang, Yang YoungSen, Ma Ming-Chun, Wang Po-Nan, Sheen Jiunn-Ming, Wang Shih-Chung, Chen Shih-Hsiang, Jaing Tang-Her, Cheng Chao-Neng, Yeh Ting-Chi, Lin Tung-Huei, Shih Lee-Yung

Многоцентровое исследованиеСтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

The direct comparison of molecular responses of front-line imatinib (IM) monitored at the same laboratory between children and adults with chronic phase (CP) of chronic myeloid leukaemia (CML) had not been reported. In this multicenter study, we compared the landmark molecular responses and outcomes of paediatric and adult CML-CP cohorts treated with front-line IM in whom the BCR::ABL1 transcript levels were monitored at the same accredited laboratory in Taiwan.

METHODS

Between June 2004 and July 2020, 55 newly diagnosed paediatric and 782 adult CML-CP patients, with molecular diagnosis and monitoring at the same reference laboratory in Taiwan, were enrolled. The criteria of 2020 European LeukemiaNet were applied to evaluate the molecular responses.

RESULTS

By year 5, the cumulative incidences of IS <1%, MMR, MR4.0 and MR4.5 of paediatric patients were all significantly lower than those of adult patients (58 vs 75%, 48 vs 66%, 25 vs 44%, 16 vs 34%, respectively). The 10-year progression-free survival (PFS) (90%) and overall survival (OS) (94%) of paediatric patients did not differ from those (92%) of adult patients.

CONCLUSIONS

We demonstrated the paediatric cohort had slower molecular responses to front-line IM and similar outcomes in 10-year PFS and OS in real-world practice.

Для цитирования: Liu Hsi-Che, Kuo Ming-Chung, Wu Kang-Hsi, Chen Tsai-Yun, Chen Jiann-Shiuh, Wang Ming-Chung, Lin Tung-Liang, Yang YoungSen, Ma Ming-Chun, Wang Po-Nan, Sheen Jiunn-Ming, Wang Shih-Chung, Chen Shih-Hsiang, Jaing Tang-Her, Cheng Chao-Neng, Yeh Ting-Chi, Lin Tung-Huei, Shih Lee-Yung. Children with chronic myeloid leukaemia treated with front-line imatinib have a slower molecular response and comparable survival compared with adults: a multicenter experience in Taiwan.. British journal of cancer. 2023. DOI: 10.1038/s41416-023-02162-9.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.